Image pharmaphorum Editor Views & Analysis COVID-19 has propelled the regulatory industry years ahead Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape. News Spark to use CombiGene therapy to target focal epilepsy Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on rea Sales & Marketing Launch excellence: escaping the complexity trap IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world. News Positive safety data for long-term use of MS drug Kesimpta Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods. Load more results
Views & Analysis COVID-19 has propelled the regulatory industry years ahead Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape.
News Spark to use CombiGene therapy to target focal epilepsy Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on rea
Sales & Marketing Launch excellence: escaping the complexity trap IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world.
News Positive safety data for long-term use of MS drug Kesimpta Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods.
News New NHS diabetes strategy could raise GLP-1 drug use New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
